| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
84,571,000 |
| Market
Cap: |
160.68(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.7304 - $3.24 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s first two products were approved by the U.S. Food and Drug Administration, European Medicines Agency, and Swiss Agency for Therapeutic Products. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
59,611 |
74,217 |
| Total Buy Value |
$0 |
$0 |
$86,148 |
$171,738 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
4 |
7 |
| Total Shares Sold |
0 |
0 |
1,913 |
51,775 |
| Total Sell Value |
$0 |
$0 |
$2,686 |
$239,770 |
| Total People Sold |
0 |
0 |
1 |
4 |
| Total Sell Transactions |
0 |
0 |
5 |
26 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcgovern Mark E |
Director |
– • – |
2020-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,106 |
16,073 |
|
- |
|
| Gotto Antonio M Jr MD D Phil |
Director |
– • – |
2020-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,106 |
11,073 |
|
- |
|
| Berkowitz Jeffrey |
Director |
– • – |
2020-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,106 |
11,073 |
|
- |
|
| Vitullo Nicole |
Director |
– • – |
2020-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,106 |
19,392 |
|
- |
|
| Woody Tracy M |
Director |
– • – |
2020-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,106 |
16,040 |
|
- |
|
| Fuhrman Alan |
Director |
– • – |
2020-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,221 |
12,878 |
|
- |
|
| Shepard Jay |
Director |
– • – |
2020-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,106 |
11,073 |
|
- |
|
| Fuhrman Alan |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
11,003 |
11,657 |
|
- |
|
| Fuhrman Alan |
Director |
– • – |
2020-03-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
654 |
|
46% |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2020-03-11 |
4 |
B |
$43.00 |
$107,500 |
D/D |
2,500 |
111,998 |
2.81 |
9% |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2020-02-28 |
4 |
B |
$49.00 |
$245,000 |
D/D |
5,000 |
109,498 |
2.81 |
2% |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2020-01-23 |
4 |
B |
$52.12 |
$1,042,398 |
D/D |
20,000 |
3,747,964 |
2.45 |
-19% |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
23,150 |
104,498 |
|
- |
|
| Bartram Richard |
Chief Financial Officer |
• – – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
7,525 |
18,673 |
|
- |
|
| Glickman Mark A |
Chief Commercial Officer |
• – – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,925 |
25,925 |
|
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2019-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
365 |
81,348 |
|
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2019-11-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,950 |
81,173 |
|
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2019-11-06 |
4 |
B |
$36.98 |
$184,900 |
D/D |
5,000 |
83,663 |
2.81 |
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2019-11-06 |
4 |
B |
$37.30 |
$2,797,560 |
D/D |
75,000 |
3,727,964 |
2.45 |
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2019-09-06 |
4 |
B |
$35.25 |
$88,125 |
D/D |
2,500 |
78,663 |
2.81 |
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2019-09-04 |
4 |
B |
$33.78 |
$2,702,208 |
D/D |
80,000 |
3,652,964 |
2.45 |
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2019-09-04 |
4 |
B |
$33.42 |
$170,982 |
D/D |
5,000 |
76,163 |
2.81 |
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2019-08-01 |
4 |
B |
$39.56 |
$197,800 |
D/D |
5,000 |
71,163 |
2.81 |
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2019-07-23 |
4 |
B |
$42.65 |
$2,132,565 |
D/D |
50,000 |
3,572,964 |
2.45 |
- |
|
| Mayleben Timothy M |
President & CEO |
• • – |
2019-06-28 |
4 |
B |
$46.00 |
$230,000 |
D/D |
5,000 |
66,163 |
2.81 |
- |
|
250 Records found
|
|
Page 4 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.09 (4.52%) 
